

## **Minutes of the Meeting of the ESH Scientific Council**

**Barcelona, June 8, 2018**  
**8:15 – 13:00 hrs**

### **Present**

K. Tsioufis, President  
E. Lurbe, Vice President  
R. Kreutz, Secretary  
M. Bochud, Treasurer  
E. Agabiti Rosei, Immediate Past President

### **ESH Council members**

M. Azizi  
A. Januszewicz  
T. Kahan  
J. Polonia  
P. van de Borne  
B. Williams

### **Executive officers**

G. Mancia  
G. Parati  
D. Clement  
A. Coca  
A. Manolis

### **Ex-officio members**

C. Borghi  
D. Lovic

### **Further Participants**

M. Burnier (from 11:00 hrs)  
M. Massaro - AIM  
R. Lynch

### **Apologies**

P. van de Borne

## 1. PRESIDENT'S WELCOME

The meeting was opened by the ESH President K. Tsioufis who welcomed Council members to the Annual Meeting. He suggested covering only the most important issues in this meeting and to refer all other issues to the Council Meeting in November.

## 2. MINUTES OF THE BARCELONA SCIENTIFIC COUNCIL MEETING, FEBRUARY, 2018

The minutes of the Council Meeting held in Barcelona, February, 2018 were unanimously accepted by the Council.

## 3. TREASURER'S REPORT

### a. ESH

M. Bochud presented the audited financial report at 31.12.2017. The total assets of the ESH amount to 2'068'681.83 Swiss francs. The net result for the year amounts to 490'477.01 Swiss francs. Total cash amounts to 1'261'221.58 Swiss francs. She pointed out that after consulting with M. Burnier, the Auditors admonished that the FESH reserves are too low compared to the amount of €700.000 when the FESH was founded. They suggested that €300.000 be transferred by ESH to FESH. This suggestion was unanimously accepted by the Council. M. Burnier reported the Auditors.

European Society of Hypertension, Zug			
Balance sheet as at 31 December (in Swiss francs)			
Assets	Notes	2017	2016
<b>Current assets</b>			
Cash and cash equivalents	3	1'261'221.58	797'500.25
Short-term investments with a quoted market price		539'211.35	497'854.00
Securities (cost price)		703'914.76	703'914.76
Valuation on securities		-164'703.41	-206'060.76
Trade receivables		149'055.10	158'215.50
due from third parties		149'055.10	158'215.50
Other current receivables		2'178.70	7'356.05
due from third parties		2'178.70	7'356.05
Accrued income and prepaid expenses		117'015.10	114'138.12
<b>Total assets</b>		<b>2'068'681.83</b>	<b>1'575'063.92</b>
<b>Liabilities</b>			
<b>Short-term liabilities</b>			
Accrued expenses and deferred income		29'273.00	28'132.10
<b>Total short-term liabilities</b>		<b>29'273.00</b>	<b>28'132.10</b>
<b>Equity</b>			
Society capital		536'044.99	536'044.99
Retained earnings		1'012'886.83	934'857.81
Net result for the year		490'477.01	78'029.02
<b>Total Equity</b>		<b>2'039'408.83</b>	<b>1'548'931.82</b>
<b>Total liabilities</b>		<b>2'068'681.83</b>	<b>1'575'063.92</b>

European Society of Hypertension, Zug			
Profit and loss statement for the financial year ended 31 December (in Swiss francs)			
	Notes	2017	2016
Net proceeds from sales of goods and services	1'582'158.89	1'377'519.75	
Subscriptions	382.15	754.15	
Various meeting income	197'337.90	62'262.40	
Income Meeting Milan	1'266'488.01	-	
Income Meeting Paris	-	1'202'144.25	
Royalties received	117'950.83	112'358.95	
Purchase and manufacturing costs of products and services sold	-1'122'762.98	-1'182'478.65	
Donations	-	-11'044.00	
Various meeting costs	-89'923.28	-77'450.40	
Expenses Meeting Milan	-1'041'502.18	-	
Expenses Meeting Paris	-	-1'041'344.25	
Awards granted	-11'327.50	-	
Joint ESC/ESH Guidelines for the mgmt of Arterial Hypertension	-	-32'640.00	
Other operating expenses	-91'759.62	-106'101.72	
Administrative costs	-8'061.60	-7'806.40	
Legal- and professional fees	-22'235.25	-33'157.75	
Other expenses	-8'005.80	-13'137.75	
Bank charges	-3'542.97	-2'301.82	
Website expenses	-49'914.00	-49'698.00	
Financial income	129'553.90	321.10	
Dividend and interest on securities	247.95	262.65	
Credit interest	-	58.45	
Gain on securities	41'357.35	-	
Gain on currency exchange	86'948.60	-	
Financial expenses	-	-17'727.51	
Loss on securities	-	-6'355.05	
Loss on currency exchange	-	-9'372.46	
Extraordinary, non-recurring or prior-period income	2'276.80	-	
<b>Result before taxes</b>	<b>498'477.01</b>	<b>91'532.97</b>	
Direct taxes	-8'000.00	-13'503.95	
<b>Net result for the year</b>	<b>490'477.01</b>	<b>78'029.02</b>	

## b. ESH FOUNDATION

M. Burnier presented the financial report of the Foundation of ESH at 31.12.2017. The total assets were 290'285.41 Swiss francs. The net result for the year amount to 5'736.76 Swiss francs. Total cash amounts to 240'546.21 Swiss francs.

No funds were transferred by ESH to FESH in 2016-2017. He suggested to make a transfer. K. Tsioufs confirmed the transfer of 300,000 Euro to the FESH. K. Tsioufis confirmed that this transfer was unanimously accepted by the Council.

FOUNDATION (FESH)			
Foundation of the European Society of Hypertension, Zug			
Balance sheet as at 31 December (in Swiss francs)			
Assets	Notes	2017	2016
<b>Current assets</b>			
Cash and cash equivalents	240'546.21	351'964.89	
Short-term investments with a quoted market price	40'491.40	420'16.05	
Securities (cost price)	58'334.00	58'334.00	
Valuation on securities	-17'842.60	-16'317.95	
Trade receivables	9'248.00	-	
due from third parties	9'248.00	-	
<b>Total current assets</b>	<b>290'285.61</b>	<b>393'580.94</b>	
<b>Total assets</b>	<b>290'285.61</b>	<b>393'580.94</b>	
<b>Liabilities</b>			
<b>Short-term liabilities</b>			
Trade payables	6'000	9'227	
due to third parties	6'000	9'227	
Accrued expenses and deferred income	16'000.00	40'331.47	
<b>Total short-term liabilities</b>	<b>22'000.20</b>	<b>49'558.77</b>	
<b>Equity</b>			
Foundation capital	700'000.00	700'000.00	
Retained earnings	-355'977.83	-227'889.55	
Net result for the year	-75'736.76	-128'088.28	
<b>Total Equity</b>	<b>268'285.41</b>	<b>344'022.17</b>	
<b>Total liabilities</b>	<b>290'285.61</b>	<b>393'580.94</b>	

Foundation of the European Society of Hypertension, Zug

**Profit and loss statement for the financial year  
ended 31 December**  
(in Swiss francs)

# FOUNDATION (FESH)

	Notes	2017	2016
Net proceeds from sales of goods and services		14'663.95	16'214.61
<i>Subscriptions of Organisations</i>		6'489.60	2'197.90
<i>Contributions to Summer School</i>		-	5'440.71
<i>Contributions to Educational Meeting</i>		5'850.75	8'576.00
<i>General meeting income</i>		2'323.60	-
Purchase and manufacturing costs of products and services sold		-74'355.43	-125'825.81
<i>Foundation activities: Summer School</i>		-62'504.48	-108'022.51
<i>Foundation activities: Educational Meeting</i>		-11'850.95	-17'803.30
Other operating expenses		-25'346.43	-26'539.76
<i>Administrative costs</i>		-21'023.75	-23'554.00
<i>Legal- and professional fees</i>		-3'888.00	-2'547.85
<i>Bank charges</i>		-434.68	-437.91
Financial income		10'825.80	8'062.68
<i>Dividend and interest on securities</i>		901.65	953.65
<i>Gain on securities</i>		-	294.35
<i>Gain on currency exchange</i>		9'924.15	6'814.68
Financial expenses		-1'524.65	-
<i>Loss on securities</i>		-1'524.65	-
<b>Net result for the year</b>		<b>-75'736.76</b>	<b>-128'088.28</b>

#### 4. ESH 2018

The annual meeting is the most important activity of the Society and K. Tsioufis thanked A. Coca and M. Massaro for the excellent organization of the 2018 ESH meeting in Barcelona.

##### a. Report on 2018 ESH Meeting, Barcelona

M. Massaro summarized the status of the 2018 Annual Meeting in Barcelona. There is a higher income with less registered participants in 2018 than in 2017. The number of free registrations in 2018 was reduced. Final numbers will be provided at the Council meeting in November.

28 <sup>th</sup> EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION		BUDGET	
PROVISIONAL		Please note that the minimum values guaranteed to the ESH and to the LOC are already calculated in this prospect. (€ 100.000,00 each)	
Sponsorship incomes – confirmed (less € 260.000 – ESH 2017)	€ 823.375,00		
Registrations - updated to 07-06-2018	€ 1.106.633,00		
Expenditures - preliminary	€ 1.897.925,00		
<b>PRELIMINARY RESULT</b>	<b>€ 32.083,00</b>		

A total of 1145 Abstracts were received. 1015 Abstracts and 121 Late-breaker abstracts were accepted. 190 were not included in the Abstract Book due to lack of registration fee payment and 24 were withdrawn by the authors. The countries that submitted the most abstracts were Italy, Russia and Spain. The e-Supplement 1 – ESH Abstract Book was

published in the June edition of the Journal of Hypertension. The Abstract Book is available on the Journal of Hypertension website, the ESH website and the ESH congress website.

M. Massaro provided costs for the publication of 922 meeting Abstracts. The cost for the online publication was €11.828,09. R. Kreutz reported that the proposal from the last Council meeting to explore the possibility to publish the abstracts in Blood Pressure was evaluated. However, as agreed the proposal by this Journal was rejected as the costs are in fact even somewhat higher compared to the Journal of Hypertension.

282 Faculty members were invited. The 2018 ESH meeting hosted 1 Sponsored Lecture (Menarini Group), 2 Satellite Symposia (Servier, Merck KGaA), 1 Hands-on Session (Somnomedics), 10 Minisymposia (CVRx, Ferrer (2), Medtronic, Menarini Group (2), Omron Healthcare Europe, ReCOR Medical, Servier (2)).

The 2018 ESH meeting hosted 26 Exhibitors in a total surface of approx. 470 SQM. The total number of registered participants in 2018 is 2565.

A brief brainstorming followed on how to reduce costs of the Annual Meeting and how to attract participants and sponsors. Ideas discussed:

- reduce the length of the congress
- begin on Thursday and finish on Sunday
- work closely with the National Societies encouraging them to bring more physicians
- involvement of local society in meeting organization to bring financial support from local sponsors
- invite local society to hold their meeting (½ day) at the ESH Annual Meeting
- provide special registration fees for Latin American countries
- take into consideration Ramadan when programming the annual meeting

## b. Awards

The awards committee selected from nominations received the below awards. Prof. Beauflis unable to participate; M. Azizi will receive the Paul Milliez Award on his behalf.

4. ESH 2018	
<p>Members of the Award Committee</p> <p>K. Tsioufis E. Agabiti Rosei E. Lurbe A. Coca R. Kreutz</p> <p>February 2018: announcement on website and per Email circulation among ESH members; deadline March 30, 2018</p> <p>Selection of winners during TC with all committee members participating on May 2, 2018</p>	<p></p> <p><b>ESH AWARDS 2018</b></p> <ul style="list-style-type: none"> <li>• <b>ALBERTO ZANCHETTI LIFE ACHIEVEMENT AWARD</b> Prof. Sverre E. Kjeldsen</li> <li>• <b>ESH HONORARY MEMBER</b> Prof. Patricio Lopez-Jaramillo</li> <li>• <b>BJÖRN FOLKOW AWARD &amp; LECTURE</b> Prof. Dominik N. Müller</li> <li>• <b>TALAL ZEIN AWARD</b> Prof. Costas Thomopoulos</li> </ul>





## c. Presentation of 2018 ESC/ESH Guidelines on the management of Arterial Hypertension







Despite the many difficulties the 2018 European Guidelines will be presented at the ESH 2018 Annual Meeting.

K. Tsioufis thanked the two chairs G. Mancia and B. Williams for their excellent contribution and efforts in preparing the Guideline publication.

K. Tsioufis informed the Council members that the Amendment to the agreement with ESC granted ESH the right to broadcast the presentation of the Guidelines in live streaming.

The full text of the new joint Guidelines will be published on August 25 in the European Heart Journal and the Journal of Hypertension, in parallel with a corresponding presentation during the ESC congress in Munich. The Guidelines will be published on the ESH website on the same day.

2018 ESC/ESH Guidelines: Amendment to agreement June 2018		
 <b>ESC</b> European Society of Cardiology COMMITTEE FOR PRACTICE GUIDELINES (CPG)		
<p>Re: 2018 ESC/ESH Guidelines for the management of arterial hypertension</p> <p><u>Amendment to the agreement dated 4 October 2016 (the "Agreement")</u></p> <p>Between</p> <p>The European Society of Hypertension (ESH), representing 37 affiliated Societies, a Swiss association with ID: CH-170.6.000.149-5 whose registered offices are at c/o Hausheer &amp; Partner Rechtsanwälte, Bahnhofstrasse 10, CH-6301 Zug No Intra-community VAT number, represented by Professor Konstantinos Tsioufis in his capacity as President, who has signing authority on behalf of the European Society of Hypertension.</p> <p>And</p> <p>The European Society of Cardiology (ESC), representing 56 ESC member societies, Society governed by the law dated 1st July 1901, whose intra-community VAT number is FR 89 403 299 480 whose registered offices are at 2035 route des Colles, Sophia Antipolis, France, represented by Mrs Isabel Bardinet, in her capacity as Chief Executive Officer, who has signing authority on behalf of the European Society of Cardiology.</p> <p>The parties have decided to modify the Agreement as follows:</p>		
<p>3. This amendment represents an additional clause, part of the Agreement. All terms and conditions of the Agreement not modified by this amendment shall remain in full force and effect.</p> <p>This amendment shall take effect from the signature by all the parties.</p> <p>IN WITNESS WHEREOF, the parties hereto caused this amendment to be executed by their duly authorized representatives:</p> <p>Made in two original copies.</p> <p>One signed original copy for ESH files, and one signed original copy for ESC files.</p>		
<p>Signed by: Professor Konstantinos Tsioufis President on behalf of the European Society of Hypertension (ESH)</p>	<p>Date: 1<sup>st</sup> June 2018 Signature: </p>	
<p>Signed by: Mrs Isabel Bardinet Chief Executive Officer on behalf of the European Society of Cardiology (ESC)</p>	<p>Date: 05/06/18 Signature: </p>	

2018 ESC/ESH Guidelines: Agreement 2016		
 <b>ESC</b> European Society of Cardiology COMMITTEE FOR PRACTICE GUIDELINES (CPG)		
<p>Re: 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension</p> <p>THIS AGREEMENT dated 04 October 2016</p> <p>BETWEEN</p> <p>The European Society of Hypertension (ESH), representing 37 affiliated Societies, a Swiss association with ID: CH-170.6.000.149-5 whose registered offices are at c/o Hausheer &amp; Partner Rechtsanwälte, Bahnhofstrasse 10, CH-6301 Zug No Intra-community VAT number, represented by Professor Enrico Agabiti Rosati, in his capacity as President, who has signing authority on behalf of the European Society of Hypertension, herein referred to as the "ESH",</p> <p>AND</p> <p>The European Society of Cardiology, Society governed by the French law dated 1st July 1901, whose intra-community VAT number is FR 89 403 299 480 whose registered offices are at 2035 route des Colles, CS 80179 Biot, Sophia Antipolis, France, represented by Mrs Isabel Bardinet, in her capacity as Chief Executive Officer, who has signing authority on behalf of the European Society of Cardiology, herein referred to as the "ESC",</p>		
<p>The termination may also be terminated due to lack of additional funding (as set out in section 3, paragraph 2 and in the absence of final approval of the Guidelines).</p> <p>In the event of Termination prior to publication, the Party responsible for the breach shall transfer back all materials owned by the other Party which were communicated within the scope of this Agreement. Neither Party shall be entitled to use any intellectual property created or co-created under this Agreement. In case of an early termination, ESC shall provide a final accounting statement. There shall be no reimbursement for funds already spent. A possible surplus will be distributed equitably amongst the Parties.</p> <p>The terms of the section 4; 5; 7; 8 shall survive the termination of the Agreement.</p> <p><b>12. Law and Jurisdiction</b></p> <p>This contract shall be governed by French laws and the Parties agree to submit to the exclusive competent jurisdiction of the Tribunal de Grande Instance de Grasse, France.</p> <p><b>13. Miscellaneous</b></p> <p>a. The terms of this Agreement set forth the entire understanding between the Parties.</p> <p>b. The Parties are neither partner nor does this joint development create any obligations outside of this project, and no party has the power to obligate or bind the other party in any manner whatsoever.</p> <p>Made in two original copies.</p>		
<p>Signed by: Professor Enrico Agabiti Rosati President on behalf of the European Society of Hypertension (ESH)</p>	<p>Date:  Signature: </p>	
<p>Signed by: Mrs Isabel Bardinet Chief Executive Officer on behalf of the European Society of Cardiology (ESC)</p>	<p>Date:  Signature: </p>	



#### d. ESH Collaboration with National Societies

The active involvement in ESH activities is essential to strengthen relationships between ESH and the National Societies.

#### e. Individual appointments with National Society Presidents



A series of individual meetings, 25 in total, with the Presidents of the National Societies have been organized each morning over the three days of the Annual Meeting. A **Summary Sheet** was sent to all the National Societies asking them to provide an overview of their society.

D. Lovic will finish his term in 2019 as ESH representative of the National Societies. The new representative will be elected by the presidents of the National societies before the June meeting 2019.

### 5. ESH BY-LAWS UPDATE 2018

R. Kreutz summarized the procedure followed to update the current ESH By-laws dated 2002. The text, both in English and in German, was approved by the Swiss law firm Ornitag. The updated By-laws include important changes related to addressing the role of FESH, simplified criteria for membership application, corporate membership, Ex-officio non-voting members and the Awards committee. No objections were raised by the Council.

The By-laws will be presented during the ESH General Assembly for approval.

 <p><b>European Society of Hypertension</b></p> <p><b>BY-LAWS</b></p> <p><b>ARTICLE I</b></p> <p><b>European Society of Hypertension (ESH), Zug (CH)</b> The name of this organization shall be the European Society of Hypertension (ESH) and the abbreviation ESH is used in this document to refer to this organization. The ESH is a society according to art. 60 et seq. of the Swiss Civil Code. Its seat is in Zug, Switzerland.</p> <p><b>ARTICLE II</b></p> <p><b>Purpose</b> The objectives of the Society shall be to promote and encourage the advancement of scientific research and knowledge in hypertension and associated diseases. It shall also be to promote and encourage application of the knowledge to medical care in all aspects of hypertension and associated diseases. Specifically:</p> <ol style="list-style-type: none"> <li>1. The ESH will encourage, promote, endorse or organize high quality international scientific activities and communications of the results. Such activities shall be carried out primarily by an annual European Meeting as well as through the organization, participation and co-organization of special scientific and educational meetings worldwide. They shall also be carried out by means of special publications. Research projects may be sponsored or conducted under the special circumstances appropriate to international scientific bodies.</li> <li>2. The ESH will encourage, promote, endorse or organize activities involved with continuing medical education in the field of hypertension and associated diseases. This will be done also in conjunction with other scientific societies and members of health care professions.</li> <li>3. The ESH will encourage, promote, endorse or organize, alone or in conjunction with other scientific societies and members of health delivery professions, postgraduate training and international exchange of investigators, teachers, fellows and students.</li> <li>4. The ESH supports a Foundation (FESH) in order to achieve its purpose, especially but not limited to grant financial assistance for educational and research purposes. The ESH shall donate to FESH any surplus which are not necessary for achieving its purpose.</li> <li>5. The duration of the ESH is undetermined.</li> </ol> <p>1</p>	 <p><b>European Society of Hypertension</b></p> <p><b>STATUTEN</b></p> <p><b>ART. I</b></p> <p><b>Name, Sitz</b> Unter dem Namen European Society of Hypertension (Europäischer Verein zur Förderung der wissenschaftlichen Forschung im Bereich des Bluthochdrucks), im folgende Text als ESH benannt, besteht mit Sitz in Zug, Schweiz, ein Verein gemäß Art. 60ff.ZGB.</p> <p><b>ART. II</b></p> <p><b>Zweck</b> Der Verein bezweckt die Förderung und Unterstützung der wissenschaftlichen Forschung und der Kenntnisse im Bereich Bluthochdruck und assoziierten Erkrankungen. Er soll auch die Umsetzung dieser Kenntnisse bei der medizinischen Betreuung von Patienten im Bereich Bluthochdruck und den damit assoziierten Erkrankungen fördern und unterstützen.</p> <p><b>Inbesondere:</b></p> <ol style="list-style-type: none"> <li>1. Der Verein fördert, unterstützt, begünstigt und organisiert anspruchsvolle internationale wissenschaftliche Tätigkeiten sowie die Bekanntgabe deren Ergebnisse. Solche Tätigkeiten finden in erster Linie im Rahmen einer jährlichen Europäischen Versammlung statt sowie durch die Teilnahme an und Mitorganisation von internationalen Tagungen weltweit. Diese Aktivitäten umfassen weiterhin Publikationen. Die finanzielle Unterstützung oder Durchführung von Forschungsprojekten soll gemäß den für internationale wissenschaftliche Organisationen geeigneten Bedingungen erfolgen.</li> <li>2. Der Verein fördert, unterstützt, begünstigt und organisiert Tätigkeiten, welche mit der medizinischen Weiterbildung im Bereich Bluthochdruck und den damit verbundenen Erkrankungen in Verbindung stehen. Dies erfolgt in Zusammenarbeit mit anderen wissenschaftlichen Organisationen sowie mit Mitgliedern von medizinischen Berufen.</li> <li>3. Allein oder in Zusammenarbeit mit anderen wissenschaftlichen Organisationen und Mitgliedern von medizinischen Berufen fördert, unterstützt, begünstigt und organisiert der Verein die Weiterbildung von Personen, welche den Bachelor-Abschluss besitzen, sowie internationale Austauschaufenthalte von Forschern, Lehrern, medizinischen Mitarbeitern, und Studierenden.</li> <li>4. Der Verein unterstützt um seine Ziele zu verfolgen, eine Stiftung (FESH), welche insbesondere, aber nicht ausschließlich, finanzielle Unterstützung zur</li> </ol> <p>1</p>
---	---

## 5. ESH BY-LAWS UPDATE 2018

### ARTICLE III

#### Members

1. Membership in the ESH is open to physicians and any health care professionals worldwide who are dedicated to research in hypertension, or prevention and treatment (management) of hypertension and associated diseases.
2. Election of Members. Applicants are required to apply online at the website of the ESH and are requested to provide:
  - a) a short curriculum vitae (CV) in English (listing academic degrees and professional positions);
  - b) bibliography of publications related to hypertension and associated diseases;
  - c) letters of endorsement are not required. Approval of memberships are officially confirmed during the Annual Meeting of the ESH.
3. ESH members shall pay annual dues, in the amount determined by the ESH Scientific Council and approved by the General Assembly of the ESH. ESH members shall subscribe to the official Journal of the ESH.
4. **Emeritus ESH Members**  
A long-standing member of ESH over the age of 65 and who has retired from active work may seek Emeritus status by applying to the ESH President in writing. Applicants for Emeritus Membership will be approved by the ESH Scientific Council. Emeritus members may be exempted from annual dues but not from subscription costs to the official Journal of the ESH.
5. **Honorary ESH Member**  
Individuals who have made extraordinary contributions to research in hypertension or who have given exceptionally important support to the activities of the ESH may be nominated as Honorary Members. Nominations will be considered by the Awards Committee which will bring recommendations to the Scientific Council.  
This distinction will be limited to a very select group of individuals, and normally no more than one honorary member will be nominated at any one Scientific Meeting. Honorary members will be exempted from annual dues but not from subscription costs to the official Journal of the ESH.
6. **Rights and Privileges of ESH members**  
ESH members participate in the scientific and business sessions of the ESH and vote at the General Assembly during the Annual Meeting. ESH members shall be eligible for election to the ESH Scientific Council.
7. **Corporate membership**  
Institutions or companies interested in the support of hypertension research or

### Penalties

Membership shall cease automatically upon failure to pay the annual dues for two consecutive years.

### ARTICLE IV

#### ESH Scientific Council, Officers, Committees and Governing bodies.

1. **ESH Scientific Council**  
The Scientific Council of the ESH is the executive organ of the ESH. The Scientific Council has the duty of supervising all affairs of the ESH. While membership in the ESH is open to applicants worldwide, only ESH members who are European residents are eligible to become a Scientific Council member.
2. **Composition of the ESH Scientific Council**  
The ESH Scientific Council is formed by 11 elected members (including office bearers), by non-voting ex-officio members and by non-voting Executive officers nominated by the Council for specific matters.
3. **Election of the ESH Scientific Council**  
ESH Scientific Council members shall be elected as follows: at the time of the General Assembly during the Annual Meeting of the ESH, the Society shall vote on membership of the ESH Scientific Council for the succeeding four years, giving due consideration to the recommendations of the existing Scientific Council. Any six members of the Society may nominate a candidate by writing to the Secretary of the ESH Scientific Council not less than ninety days before the scheduled Annual Meeting of the ESH. Members of the Scientific Council may serve not more than two consecutive four-year terms.
4. **Ex-Officio Members**  
Ex-Officio non-voting members of the Scientific ESH Council are:
  - a) one ESH member designated by the International Society of Hypertension;
  - b) one ESH member representing PESQ;
  - c) one ESH member representing National Hypertension Societies;
 The ex-officio members shall serve for a two-year term with the option to renew the appointment for two more years.
5. **Office bearers**  
Office bearers of the Society are: the President, the Vice-President, the Secretary, the Treasurer and the Officer at Large. They are elected by the Society from the elected members of the ESH Scientific Council whose terms is continuing for at least two further years. Office bearers are elected at the time of the General Assembly during the Annual Meeting, giving due consideration to the recommendations of the ESH Scientific Council. The President shall serve for a two-year term and shall subsequently remain in the ESH Scientific Council for two more years as immediate Past-President. The Vice-President shall normally serve for two years.



## 5. ESH BY-LAWS UPDATE 2018

### 6. Non-voting Executive Officers

The ESH Scientific Council may appoint executive officers with specific responsibilities in areas that are regarded by the ESH Scientific Council to require expert attention and decisions on a continuous basis. They can be selected from among ESH Scientific Council members, regular ESH members or non-members on account of experience and competence. Executive officers selected from regular ESH members or non-members will normally be nominated by the ESH President to attend the ESH Scientific Council meeting or a portion of the meeting but may not vote or be elected to position of office bearers. Areas to be considered for executive officer appointments are:

- a) Clinical Hypertension Specialist activities
- b) ESH excellence centres
- c) Coordination of Working Group activities
- d) ESH Summer Schools
- e) Educational/Research activities of the Society
- f) Liaison with other national hypertension societies and World Hypertension League

### 7. Awards Committee

This Committee will be chaired by the President of the Society (or a delegate nominated by him from among the Scientific Council members), the Secretary of the Society and at least 3 other members nominated by the Council. This Committee will review the availability and financial support of ESH awards for each year. The Committee will provide recommendations to the Scientific Council with regard to the selection of the individuals to be given the Awards and to the selection of honorary and emeritus members of the Society. The Award Committee will normally operate for a two-year term.

### 8. Duties of the ESH Scientific Council

- a) Of the elected members of the ESH Scientific Council six shall constitute a quorum.
- b) The ESH Scientific Council should normally meet at least twice a year. Meetings should be convened by the ESH President. Additional individuals may be invited by the President to participate at an ESH Scientific Council meeting. Any group of six Scientific Council members may request by letter the President to convene an extraordinary additional meeting of the ESH Scientific Council provided requests are motivated by valid reasons.
- c) The Secretary of the Society shall inform all ESH Council members of the Agenda of the ESH Scientific Council meeting at least 14 days before the meeting is held. Council members may request the President by letter to include additional items in the Agenda at least 30 days before the ESH Scientific Council meeting.

### 9. Governing bodies

The ESH shall encompass the following bodies: the General Assembly, the ESH Scientific Council, and one or more auditors. The General Assembly shall be held at the time of the Annual Scientific Meeting of the Society. Only topics listed in the Agenda may be brought up for discussion at the AGM. Any other matters shall be referred

to include items in the Agenda must be addressed to the President at least six weeks before the General Assembly is to meet.

### ARTICLE V

**Meetings**  
The Society will usually convene one General Scientific Meeting every year. At each General Scientific Meeting, a General Assembly shall take place.

### Finances

The fiscal year of the Society shall be the calendar year.

### Audit

On the recommendation of the ESH Scientific Council and with the approval of the General Assembly, the Society shall employ an accounting firm to prepare and distribute an annual review of the finances of the Society and to provide such other services as deemed necessary by the ESH Scientific Council, the President and the Treasurer.

### ARTICLE VI

#### Cooperation

The Society shall seek to coordinate its activity with other similar societies in other parts of the world.

### ARTICLE VII

#### Amendments to by-laws

Amendments to the by-laws of the ESH must be proposed in writing to the ESH Scientific Council by six or more members not less than ninety days before a General Assembly. The Agenda of which shall contain an announcement of the proposed amendment. Such amendments require for their adoption an affirmative vote of two-thirds of those present at the General Assembly. A postal vote may be held at the discretion of the ESH Scientific Council. The amendment shall become an active part of the by-laws immediately after the end of the General Scientific Meeting or after completion of the postal vote.

#### Council resolutions

Separately from the by-laws the ESH Scientific Council should maintain a schedule of formal Council resolutions that will help guide its processes. These will include resolutions in the following areas:

1. Guidelines for Conduct of Satellite
2. Arrangements for Annual Scientific Meeting
3. Arrangements for Voting Faculty
4. Procedures for recording official ESH endorsement of Scientific Meeting in the field of Hypertension



## 6. FUTURE MEETINGS

### a. 2019 ESH Meeting, Milan

The meeting will be held 21-24 June, 2019. The layout will be similar to the 2017 layout.

### b. 2020 ESH/ISH Meeting, Glasgow

The agreement between ESH/ISH will be signed during the meeting on June 11.

The City of Glasgow and Tourist Bureau have committed to a financial contribution which is contingent to the number of participants.



**c. 2021 ESH Meeting, Milan**

Nothing to report.

**d. 2022 BID Meeting Candidature**

The presentation of the Bid proposals will take place on Saturday, June 9. The Selection Committee will review the presentations and the announcement of the winner will be made during the General Assembly on Sunday, June 10.

**7. ESH MEMBERSHIP STATUS**

R. Kreutz provided a brief overview of the membership statistics on the payment status.

**7. ESH MEMBERSHIP STATUS**

(R. Kreutz, R. Lynch)

• ESH Members (31/01/18) - **1,742**

• ESH Members (31/05/18) - **1,818**

	2017	2018 (31/05/18)
ESH MEMBERSHIP RENEWALS	322	606

• ESH membership applications (01/06/17-31/01/18) – **120** from **48** countries worldwide

• ESH membership applications (01/02/18-31/05/18) – **181** from **58** countries worldwide

**8. ESH AND JOURNAL OF HYPERTENSION**

K. Tsioufis thanked G. Mancia for guaranteeing the smooth conduction of the Journal of Hypertension during Alberto Zanchetti's recovery in hospital and after his death.

He also announced that G. Mancia has been nominated by ESH for the Editor in Chief of the Journal of Hypertension for the next three years. G. Mancia added that in this interim period it is necessary to define new editorial management criteria. More involvement by ISH is needed and Associate Editors should be made more independent. A meeting of the Board of Management of JH to clarify the nomination/election of the new editor is scheduled on 9th June 2018

**9. ESH YOUNG INVESTIGATOR'S FORUM**

J. Polonia apologized for the delay in implementing the forum. Contacts with young physicians has brought to light that hypertension is not very interesting to them. Implement ways to attract young physicians and create interest in hypertension by inviting them to the Summer Schools, develop online program featuring hypertension and multiple diseases (Working Group topics), provide diploma. The core procedure will be presented during the Council meeting in November.

## **10. RULES AND ENDORSEMENT OF THE PRE – AND POST – SATELLITE SYMPOSIA AND INDUSTRY SUPPORTED SYMPOSIA**

T. Kahan gave a brief overview of the diversities and rules in different countries and industries regarding the endorsement of pre- and post- satellite symposia and industry supported symposia. Guidelines regulating the above endorsements will be created and will be presented at the next Council meeting.

## **11. ESH RESEARCH PROJECTS**

### **a. BP Controls in European Countries**

B. Jelakovic advised that the protocol and Informed Consent have been sent out to the participating Excellence Centres. Some Centres have requested the translation of the protocol and Informed Consent, National Societies will be asked to collaborate with the translations. Omron will deliver the devices to B. Jelakovic who will arrange shipment to the Excellence Centres. The Study will begin in September.

### **b. ESH App Pilot Study**

A grant has been received from Pfizer to fund this study which will be carried out in 6 European countries.

### **c. Atrial Fibrillation**

The enrolment of approximately 1000 patients has closed.

## **12. ESH POSITION PAPERS**

C. Borghi reported he is still waiting for contributions from authors of the Position Paper Nutraceutical for the management of high blood. The final draft will be ready for presentation during the Council Meeting in Bologna.

## **13. ESH NEWSLETTERS FOR 2018-2019**

Three new newsletters were published in 2018.

## **14. ESH ENDORSEMENT (Books, Meetings)**

The 1<sup>st</sup> North Eastern Postgraduate Course “Arterial Stiffness and Vascular Aging”, 15-16<sup>th</sup> November, 2018, Vilnius, Lithuania was endorsed.

## **15. ESH and CHL/INDIAN COLLABORATION**

E. Agabiti reported that collaboration with the India began last year. C.Tsioufis reported that Webinars will be broadcast during the Annual Meeting in Barcelona.

E. Agabiti reported the first Spring School in Beijing, China was a success and will be repeated next year. 120 doctors participated in the Spring School. A joint session with the CHL will be held during the Annual Meeting in Barcelona.

## **16. ESH SUMMER SCHOOL IN SWITZERLAND**

M. Burnier informed the Council that the final program for the Summer School is ready with the participation of around 77 young physicians.

Many applications have been received from non-European countries eg. Iraq, Yemen, Egypt, Korea, Argentina. A discussion followed on whether only European physicians should be allowed to attend. In the light of the relationships with Latin America and other non-European countries, G. Mancia suggested flexibility to accept non-European participants.

The Society should be more involved in the Summer Schools and the programme should be sent to the President for approval.

The Summer School budget is €100.000. It was suggested to involve local speakers to keep costs low.

D. Lovic accepted to host the 2020 Summer School in Serbia.

## **17. DATES FOR FUTURE COUNCIL MEETINGS**

- a. Bologna (Italy), 3 November, 2019
- b. Milan (Italy), 2019 (TBC)
- c. Milan (Italy), 21 June, 2019

## **18. ANY OTHER ISSUES**

- a. B. Jelakovic reported four applications from Austria, Belarus, Brazil, Germany for had been received for Excellence Centre status. The applications were approved.
- b. M. Burnier reported the Auditors admonished the FESH's reserves are too low compared to the capitol of €700.000 when the FESH was founded. €300.000 will be transferred by ESH to FESH.
- c. The live streaming of the Guidelines during the Annual Meeting presentation was confirmed.

## **19. CLOSURE OF THE MEETING**

K. Tsioufis thanked all the ESH Scientific Council members for attending and wished them a successful ESH meeting.



**Konstantinos Tsioufis**  
ESH President



**Reinhold Kreutz**  
ESH Secretary